GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sagimet Biosciences Inc (STU:0O2) » Definitions » Cash Flow from Discontinued Operations

Sagimet Biosciences (STU:0O2) Cash Flow from Discontinued Operations : €0.00 Mil (TTM As of Mar. 2025)


View and export this data going back to 2023. Start your Free Trial

What is Sagimet Biosciences Cash Flow from Discontinued Operations?

Cash flow from discontinued operations is the cash received by a company that comes from the sale of part of business.

Sagimet Biosciences's cash flow from discontinued operations for the three months ended in Mar. 2025 was €0.00 Mil. It means Sagimet Biosciences received €0.00 Mil from the sale of part of business quarterly. Sagimet Biosciences's cash flow from discontinued operations for the trailing twelve months (TTM) ended in Mar. 2025 was €0.00 Mil.

Sagimet Biosciences Cash Flow from Discontinued Operations Historical Data

The historical data trend for Sagimet Biosciences's Cash Flow from Discontinued Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sagimet Biosciences Cash Flow from Discontinued Operations Chart

Sagimet Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow from Discontinued Operations
Get a 7-Day Free Trial - - - - -

Sagimet Biosciences Quarterly Data
Dec19 Mar20 Dec20 Mar21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cash Flow from Discontinued Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Sagimet Biosciences Cash Flow from Discontinued Operations Calculation

Cash received by a company that comes from the sale of part of business.

Cash Flow from Discontinued Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sagimet Biosciences Cash Flow from Discontinued Operations Related Terms

Thank you for viewing the detailed overview of Sagimet Biosciences's Cash Flow from Discontinued Operations provided by GuruFocus.com. Please click on the following links to see related term pages.

Sagimet Biosciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sagimet Biosciences Inc (STU:0O2) » Definitions » Cash Flow from Discontinued Operations
Comparable Companies
NMRA BDTX ATOS SGMO VXRT ACHV LCTX AGEN OBIO ASMB VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
SGMT:USA 0O2:Germany
Address
155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402
Website
https://www.sagimet.com
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Sagimet Biosciences Headlines

No Headlines